Acambis is an integrated biotechnology company focusing on the development of novel live vaccines. The company has a product pipeline with eight vaccines against yellow fever, Japanese encephalitis, dengue fever, small pox, typhoid, traveller’s diarrhea, Helicobacter pylori and Clostridium difficile infections that are undergoing clinical development. Acambis’ small pox vaccine, ACAM2000, has been granted fast-track status by FDA. In March 2003, the company reported a pre-tax profit of US$15.4 M.